TD Cowen analyst Jason Gabelman raised the firm’s price target on Calumet (CLMT) to $19 from $18 and keeps a Hold rating on the shares. The firm updated itsestimates following 4Q guidance reflecting roll-forward of valuation to start 2026. The base business is operating well while MRL remains the more uncertain part of the business.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet price target raised to $24 from $23 at BofA
- Elliott Backs Private Hypersonic Firm as U.S. Defense Spending Accelerates
- Calumet Specialty Products Completes Upsized Senior Notes Offering
- Calumet Specialty Products Prices New Senior Notes Offering
- Calumet Specialty Products Announces New Senior Notes Offering